A novel cooling device to the arms and legs has been developed to prevent complications of chemotherapy to the peripheral nervous system. The designed cooling device can reduce nerve exposure to chemotherapy and has biofeedback mechanisms to the limbs including the monitoring of the blood flow and temperature. Successful pilot studies have been conducted with healthy and cancer subjects.
The technnology comprises of temperature and blood flow monitor and one or more inlets for fluid coolant to be delivered to the limbs of the subject. The decreased temperature primarily reduces the blood flow supplied to the peripheral nerves and toxic chemotherapeutics are directed away from the cooled organ/tissue and hence reduces neurotoxicity.
In the hospitals, clinics and medical facilities providing chemotherapy for cancer treatment and care.
The global neuropathic pain market was valued at US$ 5.4 Bn in 2016. The market is projected to expand at a CAGR of 5.6% during an eight-year forecast period 2016–2024 and reach US$ 8.3 Bn by the end of 2024 and the Chemotherapy Induced Peripheral Neuropathy segment is estimated to account for 42.4% revenue share in the global neuropathic pain market by 2016 end.